DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge
- PMID: 10639319
- DOI: 10.1006/viro.1999.0096
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge
Abstract
Previously we found that passive transfer of monoclonal antibodies (MAbs) specific to either the vaccinia virus (VACV) L1R or A33R gene product protected mice from challenge with VACV. The L1R-specific MAbs, which bind the intracellular mature virion (IMV), neutralized virus in cell culture, whereas the A33R-specific MAbs, which bind extracellular enveloped virions (EEV), did not. To investigate whether a protective response could be generated by vaccination with these genes, we constructed and evaluated DNA vaccines expressing the VACV L1R and/or A33R genes under control of a cytomegalovirus promoter. Mice were vaccinated with DNA-coated gold beads by using a gene gun and then challenged with VACV (strain WR) intraperitoneally. Mice vaccinated with L1R alone developed neutralizing antibodies and were partially protected. Mice vaccinated with a combination of both genes loaded on the same gold beads developed a robust anti-A33R response; however, no neutralizing antibody response was detected, and the mice were not protected. In contrast, when mice were vaccinated with L1R and A33R loaded on different gold beads, neutralizing (presumably anti-L1R) and anti-A33R antibody responses were detected, and protection was markedly improved. Our results indicated that vaccination with both L1R and A33R proteins, intended to evoke mechanistically distinct and complementary forms of protection, was more effective than vaccination with either protein by itself.
Copyright 2000 Academic Press.
Similar articles
-
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.Virology. 1999 Feb 1;254(1):71-80. doi: 10.1006/viro.1998.9516. Virology. 1999. PMID: 9927575
-
Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.Vaccine. 2008 Jun 25;26(27-28):3507-15. doi: 10.1016/j.vaccine.2008.04.017. Epub 2008 Apr 28. Vaccine. 2008. PMID: 18485547
-
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.Virology. 2003 Feb 1;306(1):181-95. doi: 10.1016/s0042-6822(02)00038-7. Virology. 2003. PMID: 12620810 Free PMC article.
-
The exit of vaccinia virus from infected cells.Virus Res. 2004 Dec;106(2):189-97. doi: 10.1016/j.virusres.2004.08.015. Virus Res. 2004. PMID: 15567497 Review.
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
Cited by
-
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.J Virol. 2009 Feb;83(3):1201-15. doi: 10.1128/JVI.01797-08. Epub 2008 Nov 19. J Virol. 2009. PMID: 19019965 Free PMC article.
-
Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Vaccines (Basel). 2014 Oct 17;2(4):755-71. doi: 10.3390/vaccines2040755. Vaccines (Basel). 2014. PMID: 26344890 Free PMC article. Review.
-
Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Virol J. 2012 Sep 24;9:217. doi: 10.1186/1743-422X-9-217. Virol J. 2012. PMID: 23006741 Free PMC article.
-
Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.Vaccine. 2013 Jan 2;31(2):319-26. doi: 10.1016/j.vaccine.2012.11.007. Epub 2012 Nov 12. Vaccine. 2013. PMID: 23153450 Free PMC article.
-
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.Nat Med. 2012 Aug;18(8):1291-6. doi: 10.1038/nm.2866. Epub 2012 Jul 15. Nat Med. 2012. PMID: 22797811 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources